I
Ioannis Gounaris
Researcher at Novartis
Publications - 36
Citations - 2158
Ioannis Gounaris is an academic researcher from Novartis. The author has contributed to research in topics: Breast cancer & Epirubicin. The author has an hindex of 15, co-authored 32 publications receiving 1467 citations. Previous affiliations of Ioannis Gounaris include Lynn University & Cambridge University Hospitals NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Enhanced detection of circulating tumor DNA by fragment size analysis
Florent Mouliere,Dineika Chandrananda,Anna M. Piskorz,Elizabeth Moore,Elizabeth Moore,James Morris,Lise Barlebo Ahlborn,Richard Mair,Teodora Goranova,Francesco Marass,Katrin Heider,Jonathan C. M. Wan,Anna Supernat,Anna Supernat,Irena Hudecova,Ioannis Gounaris,Ioannis Gounaris,Susana Ros,Mercedes Jimenez-Linan,Javier Garcia-Corbacho,Keval M. Patel,Olga Østrup,Suzanne Murphy,Matthew D. Eldridge,Davina Gale,Grant D. Stewart,Grant D. Stewart,Johanna Burge,Wendy N. Cooper,Michiel S. van der Heijden,Charles E. Massie,Colin Watts,Pippa Corrie,Simon Pacey,Simon Pacey,Kevin M. Brindle,Richard D. Baird,Morten Mau-Sørensen,Christine Parkinson,Christopher Smith,James D. Brenton,Nitzan Rosenfeld +41 more
TL;DR: Fragment size analysis and selective sequencing of specific fragment sizes can boost ctDNA detection and could complement or provide an alternative to deeper sequencing of cfDNA.
Journal ArticleDOI
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
Seock-Ah Im,Yen-Shen Lu,Aditya Bardia,Nadia Harbeck,Marco Colleoni,Fabio Franke,Louis W.C. Chow,Joohyuk Sohn,Keun-Seok Lee,Saúl Campos-Gómez,Rafael Villanueva-Vazquez,Kyung Hae Jung,Arunava Chakravartty,Gareth Hughes,Ioannis Gounaris,Karen Rodriguez-Lorenc,Tetiana Taran,Sara A. Hurvitz,Debu Tripathy +18 more
TL;DR: This trial showed significantly longer overall survival with a CDK4/6 inhibitor plus endocrine therapy than with endocrine Therapy alone among patients with advanced hormone-receptor-positive, HER2-negative breast cancer.
Journal ArticleDOI
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.
Christine Parkinson,Davina Gale,Anna M. Piskorz,Heather Biggs,Charlotte Hodgkin,Helen C. Addley,Sue Freeman,Penelope Moyle,Evis Sala,Karen Sayal,Karen Hosking,Ioannis Gounaris,Mercedes Jimenez-Linan,Helena M. Earl,Wendi Qian,Nitzan Rosenfeld,James D. Brenton +16 more
TL;DR: It is demonstrated that ctDNA is correlated with volume of disease at the start of treatment in women with HGSOC and that a decrease of ≤60% in TP53MAF after one cycle of chemotherapy was associated with shorter TTP, and warrants further investigation in larger cohorts receiving uniform treatment.
Journal ArticleDOI
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
Helena M. Earl,Helena M. Earl,Helena M. Earl,Louise Hiller,Anne-Laure Vallier,Shrushma Loi,Karen McAdam,Karen McAdam,Luke Hughes-Davies,Adrian Harnett,Mei-Lin Ah-See,Richard Simcock,Daniel Rea,Sanjay Raj,Pamela Woodings,Mark Harries,Donna L. Howe,Kerry Raynes,Helen B Higgins,Maggie Wilcox,Chris Plummer,Chris Plummer,Janine Mansi,Ioannis Gounaris,Betania Mahler Araujo,Elena Provenzano,Elena Provenzano,Anita Chhabra,Jean Abraham,Jean Abraham,Jean Abraham,Carlos Caldas,Peter Hall,Christopher McCabe,Claire Hulme,Claire Hulme,David Miles,Andrew M Wardley,David Cameron,Janet A. Dunn,Roshan Agarwal,Hafiz Algurafi,Rozenn Allerton,Caroline Archer,Anne C Armstrong,Catherine Bale,Lisa H Barraclough,Urmila Barthakur,Carolyn Bedi,Kim Benstead,D. Bloomfield,Rebecca Bowen,Chris Bradley,Jane Brown,Mohammad Butt,Mark Churn,Susan Cleator,Joanne Cliff,Perric Crellin,Margaret Daly,Shiroma De Silva-Minor,A.S. Dhadda,O.S. Din,Sue Down,H. M. Earl,David J. Eaton,Andrew Eichholz,Daniel Epurescu,Chee Goh,Andrew D. Goodman,Robert Grieve,Maher Hadaki,Catherine Harper-Wynne,Larry Hayward,A. Humphreys,Helen Innes,Mariam Jafri,Apurna Jegannathen,Muireann Kelleher,Hartmut Kristeleit,Daniela Lee,Susan Lupton,Carol MacGregor,Zafar Malik,Jennifer Marshall,Trevor McGolick,Rakesh Mehra,Natasha Mithal,Charlotte Moss,Aian Moss,Mukesh Mukesh,Anthony Neal,Daniel Nelmes,Helen Neville-Webbe,Jacqueline Newby,S O'Reilly,Peter Ostler,Mojca Persic,Laura Pettit,Fharat A. Raja,Catherine Reed,Anne Rigg,Helen Roe,Nihal Shah,Peter Simmonds,Eliot Sims,Sarah Smith,Nicola Storey,Wendy Taylor,Narottam Thanvi,Karen Tipples,Jayant S. Vaidya,Mohini Varughese,Anup Vinayan,Nawaz Walji,Simon Waters,Kathryn Wright,Sundus Yahya +117 more
TL;DR: 6-month trastuzumab treatment is shown to be non-inferior to 12-month treatment in patients with HER2-positive early breast cancer, with less cardiotoxicity and fewer severe adverse events, which support consideration of reduced duration trastzumab for women at similar risk of recurrence as to those included in the trial.
Journal ArticleDOI
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial
Helena M. Earl,Helena M. Earl,Louise Hiller,Janet A. Dunn,Clare Blenkinsop,L Grybowicz,Anne-Laure Vallier,Jean Abraham,Jean Abraham,Jean Abraham,Jeremy Thomas,Elena Provenzano,Elena Provenzano,Luke Hughes-Davies,Ioannis Gounaris,Karen McAdam,Stephen Chan,Rizvana Ahmad,Tamas Hickish,Stephen Houston,Daniel Rea,John M. S. Bartlett,John M. S. Bartlett,Carlos Caldas,Carlos Caldas,David Cameron,Larry Hayward +26 more
TL;DR: Addition of four cycles of bevacizumab to D-FEC in HER2-negative early breast cancer significantly improved pathological complete response, however, whether the improvement in pathologicalcomplete response will lead to improved disease-free and overall survival outcomes is unknown.